<SEC-DOCUMENT>0001818382-23-000028.txt : 20230512
<SEC-HEADER>0001818382-23-000028.hdr.sgml : 20230512
<ACCEPTANCE-DATETIME>20230512071325
ACCESSION NUMBER:		0001818382-23-000028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230512
DATE AS OF CHANGE:		20230512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		23913136

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20230512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:20006a8f-5585-4a58-b190-b567a58af272,g:8cba8344-f56d-47b0-9377-d5b25c27f06c,d:5910e17be9bc4bbd8f4df18742dd0ad7--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20230512</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN180L2ZyYWc6YjNjNzRiOTRlZWVhNGNjZWFlMjAyODUzYzU3ZjE1NWYvdGFibGU6ZjRkYTBhZmVjMTk1NGE5NzlkMzgyYmNkOTk1YTY0MTIvdGFibGVyYW5nZTpmNGRhMGFmZWMxOTU0YTk3OWQzODJiY2Q5OTVhNjQxMl8xLTEtMS0xLTgyMDIw_2925a37e-3e65-4fbb-8afd-f1c71a092ca3">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN180L2ZyYWc6YjNjNzRiOTRlZWVhNGNjZWFlMjAyODUzYzU3ZjE1NWYvdGFibGU6ZjRkYTBhZmVjMTk1NGE5NzlkMzgyYmNkOTk1YTY0MTIvdGFibGVyYW5nZTpmNGRhMGFmZWMxOTU0YTk3OWQzODJiY2Q5OTVhNjQxMl8yLTEtMS0xLTgyMDIw_cb0e7331-bef2-404b-bf59-791221480a85">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20230512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5910e17be9bc4bbd8f4df18742dd0ad7_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjI5_f21a16f2-6c84-4e13-8da8-cf64f10a4ea7">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMw_447823fd-a6e9-44b4-bc99-51e757ee7c7b">May 12, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMy_afef7265-bf93-4e66-a796-c2b880ae9cf0">Humacyte, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTAtMS0xLTgyMDIw_17b10c9c-de12-43aa-9b59-e62ca6536d07">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTEtMS0xLTgyMDIw_12bff9bd-1d9b-4efa-83fb-2262b2444b41">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTItMS0xLTgyMDIw_59c53e02-1d49-46e4-b3a2-88fdd51423f2">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8wLTAtMS0xLTgyMDIw_1987bb04-ac80-4e53-8908-5debe8ee4444">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTAtMS0xLTgyMDIw_4a872a53-a061-4a52-b5d7-b77b29c95dd2">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTEtMS0xLTgyMDIw_7519f0f2-62f6-4d73-b9a1-b1562dc73c5f">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTItMS0xLTgyMDIw_7aa39407-fe0a-4882-ad97-3dbb60c6db38">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8zMjc_326dbb38-8b87-4870-8098-079580976460">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMz_e155d3d6-0d87-479d-b05d-1f9f71abff39">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18wLTAtMS0xLTgyMDIw_89e26ea0-f87c-4956-9c28-e4874394661a">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18xLTAtMS0xLTgyMDIw_a7fde561-86d2-4888-a493-214e9e9155f8">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18yLTAtMS0xLTgyMDIw_9f7486ee-8cd4-4e84-a991-9ef405a31e05">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18zLTAtMS0xLTgyMDIw_9a9607ec-c4b6-437f-ab4a-a61ddcfd1ccb">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTAtMS0xLTgyMDIw_5cab5d14-2a92-4ebe-8894-3d202057521f">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTItMS0xLTgyMDIw_dc4fe450-64cf-4ea7-a421-d69482b31486">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTQtMS0xLTgyMDIw_6eae6334-00b8-4afd-992e-295457881956">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTAtMS0xLTgyMDIw_46614242-5be8-4ddf-b663-8ecddafd098d">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTItMS0xLTgyMDIw_9009b51b-c893-416b-8f7e-fd1ec70eb989">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTQtMS0xLTgyMDIw_4a80e7c3-d8ec-4e23-9f79-da9f1ea51f36">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjM0_b7eb74bf-b9bc-4cf6-9b8f-a7edd4d9cdbe">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjI4_ced6e777-b225-4a0f-9796-894dc0872d22">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5910e17be9bc4bbd8f4df18742dd0ad7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March&#160;31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i5910e17be9bc4bbd8f4df18742dd0ad7_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20230512xexx991.htm">Press release, dated May 12, 2023.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5910e17be9bc4bbd8f4df18742dd0ad7_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 12, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20230512xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iad7a4a62cc7a400e855abfcdfb2ca595_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:210px"></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2023 Financial Results and Business Update</font></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">- </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Human Acellular Vessel&#8482; (HAV&#8482;) granted second RMAT designation by the FDA, for Vascular Trauma -</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">- Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients -</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference call and live webcast at 8&#58;00 a.m. ET today </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:16pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DURHAM, N.C., May 12, 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissue at commercial scale, today announced financial results for the first quar</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ter ended March&#160;31, 2023, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are off to a fast start in 2023 and have moved closer to our planned filing of a Biologics License Application (BLA) for accelerated approval with the U.S. Food and Drug Administration (FDA) of our Human Acellular Vessel (HAV) for an indication in extremity vascular trauma,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;We were pleased to receive our second RMAT designation from the FDA, for use of the HAV in urgent arterial repair following extremity vascular trauma. The RMAT designation provides a higher likelihood for priority review of our planned BLA filing. We were delighted to see the potential benefits of the HAV reflected in two recent publications, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Regional Health - Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Trauma and Acute Care Surgery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Lastly, I wanted to acknowledge JDRF International for their support of our Biovascular Pancreas (BVP) preclinical program in Type 1 diabetes.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Recent Corporate Highlights</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Progress toward planned BLA filing of HAV in vascular trauma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In May 2023, Humacyte was granted the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation for the HAV for urgent arterial repair following extremity vascular trauma. The RMAT designation allows for more interactions with the FDA and expedited development and review of regenerative medicine products within the U.S., including the potential for priority review process for a BLA. The RMAT designation comes as Humacyte is nearing the anticipated completion of enrollment in its Phase 2&#47;3 V005 clinical trial of the HAV in the repair of civilian vascular trauma, a study being conducted at Level 1 Trauma Centers in the U.S. and Israel. Currently, a total of 66 patients have received the HAV in the V005 trial, including 49 patients comprising the primary endpoint population. Humacyte plans to file a BLA with the FDA later in 2023 for the treatment of extremity vascular trauma when synthetic graft is not indicated and when autologous vein is not feasible.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In March 2023, Humacyte completed enrollment of a Phase 3 trial in hemodialysis access. The Phase 3 trial, conducted in the U.S., is designed to assess the safety and efficacy of the HAV in establishing vascular access for hemodialysis patients with end-stage renal disease as compared to autogenous arteriovenous (AV) fistulas in 240 patients. Efficacy assessments include conduit patency and useability of the conduit for dialysis during the first year, with top-line results expected in 2024. The rate of dialysis-related infections in both HAV and fistula subjects will also be tracked as a secondary endpoint.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publications and Presentations</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">In May 2023, a publication in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Regional Health - Europe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> described how Ukrainian surgeons have used the HAV to save life and limb in treating battlefield and other vascular trauma injuries suffered in Ukraine-Russia conflict. Since June 2022, 19 patients (13 at time of publication submission) in Ukraine have been treated under a humanitarian program with the HAV to repair vascular trauma. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">In April 2023, publication of a preclinical study in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Journal of Trauma and Acute Care Surgery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared the use of the HAV to expanded polytetrafluorethylene (ePTFE) grafts for vascular repair following arterial trauma in a porcine model. The data observed in this preclinical study indicate that the HAV performed better than ePTFE on multiple indices, including recovery of limb function after six hours of ischemia and conduit patency. In addition, the HAV showed no incidence of infection, degradation, aneurysm or mechanical failure. Host recellularization of the HAV conduits was observed to be greater than that for ePTFE grafts.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2023 Humacyte and JDRF International (JDRF), the leading global organization funding type 1 diabetes research, announced a collaboration to advance the development of Humacyte&#8217;s BVP product candidate. Humacyte&#8217;s BVP is designed to enable the delivery and survival of insulin-producing islets using the HAV, as a treatment for type 1 diabetes. JDRF will provide Humacyte with funding to support the preclinical development and testing of the BVP.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash, cash equivalents and short-term investments of $131.7 million as of March&#160;31, 2023. Subsequent to March 31, 2023, Humacyte reported the completion of an up to $160 million funding arrangement with Oberland Capital. Humacyte believes that its cash, cash equivalents short-term investments and planned funding from the Oberland funding agreement are adequate to fund operations past the anticipated timelines for potential approval and commercialization of the HAV in vascular trauma.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was no revenue for the first quarter of 2023, compared to $0.2 million for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of 2022. Revenue for 2022 is related to a grant supporting the development of the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $17.3 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022. The current-period increase resulted primarily from increased personnel expenses to support expanded research and development initiatives and our clinical trials.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $5.2 million for the first quarter of 2023, compared to $5.7 million for the first quarter of 2022. The current-period decrease resulted primarily from reduced professional fees in 2023.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expense), was net expense of $14.5 million for the first quarter of 2023, compared to net income of $1.9 million for the first quarter of 2022. The current-period increase in other net expense resulted primarily from the remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $37.0 million for the first quarter of 2023, compared to $19.8 million for the first quarter of 2022. The current-period increase in net loss resulted from the increase in other net expense described above.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net cash used in operations was $18.6 million for the first quarter of 2023 compared to $18.8 million for the first quarter of 2022. Total net cash used was $20.2 million for the first quarter of 2023, compared to $19.3 million for the first quarter of 2022, with the current-year increase related to purchases of property and equipment to prepare for planned commercial launch of the HAV.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Friday, May 12, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; +1-201-389-0920<br>Conference ID&#58; 13738048</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Feature&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Q1 2023 Earnings Conference Call - Click Here</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase 2&#47;3 clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed by Humacyte with the SEC and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rich Luchette</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Precision Strategies</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-202-845-3924</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iad7a4a62cc7a400e855abfcdfb2ca595_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant revenue</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,278&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,314&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,682&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,512&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,996&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,512)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21,763)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,191)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (net)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,327)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,457)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,969)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(19,832)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,263,528&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,004,088&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="iad7a4a62cc7a400e855abfcdfb2ca595_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,855&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,208&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,593&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,411&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,857&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,601&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,084&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, net of current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,410&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,252&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,853&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,089</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,374</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,466&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463,507)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,538)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,887&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20230512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:20006a8f-5585-4a58-b190-b567a58af272,g:8cba8344-f56d-47b0-9377-d5b25c27f06c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20230512" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20230512">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230512_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20230512_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:20006a8f-5585-4a58-b190-b567a58af272,g:8cba8344-f56d-47b0-9377-d5b25c27f06c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230512.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended" id="if6a5c314d3b649f391bc31ec01fd5a0e_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e83fd59-001f-4e29-b0d6-c41948199ce8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_DocumentType_7e83fd59-001f-4e29-b0d6-c41948199ce8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6d070aed-30a8-4a50-9aba-8116e4867ea2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_DocumentPeriodEndDate_6d070aed-30a8-4a50-9aba-8116e4867ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2a62c530-faf6-4d9b-bd3f-28b1f6986426" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityRegistrantName_2a62c530-faf6-4d9b-bd3f-28b1f6986426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a90fe0a9-f5c8-4bb1-a8ed-bc7cc6c6ecf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a90fe0a9-f5c8-4bb1-a8ed-bc7cc6c6ecf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9ee021d9-9d4d-4250-b137-40b06848b2dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityFileNumber_9ee021d9-9d4d-4250-b137-40b06848b2dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fe0144fe-245e-445c-ac1a-6906b6c2583f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityTaxIdentificationNumber_fe0144fe-245e-445c-ac1a-6906b6c2583f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6be245e2-b98e-4246-9dd4-9c96ddff12e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressAddressLine1_6be245e2-b98e-4246-9dd4-9c96ddff12e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2191189e-3711-4725-a4e7-97077288da4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressCityOrTown_2191189e-3711-4725-a4e7-97077288da4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_893ba70f-7263-47d5-a573-ca3568d788cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressStateOrProvince_893ba70f-7263-47d5-a573-ca3568d788cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdd8b026-87dc-4587-8775-a0ac2202d47e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressPostalZipCode_fdd8b026-87dc-4587-8775-a0ac2202d47e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7ba37b07-97e4-41b2-b4a8-f770f98bef92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_CityAreaCode_7ba37b07-97e4-41b2-b4a8-f770f98bef92" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4637479e-1fe8-454b-908e-0883d0904ef6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_LocalPhoneNumber_4637479e-1fe8-454b-908e-0883d0904ef6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_60b71b93-3d0f-44c4-a8ee-f43a69bccbf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_WrittenCommunications_60b71b93-3d0f-44c4-a8ee-f43a69bccbf3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2aa913de-ae54-423b-a73a-f5a15c7c0ed5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_SolicitingMaterial_2aa913de-ae54-423b-a73a-f5a15c7c0ed5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a717e342-38f0-435c-a216-65f11e1011a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_PreCommencementTenderOffer_a717e342-38f0-435c-a216-65f11e1011a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2a3bc8ef-8d50-4883-88ea-c7aaaa1b8d23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2a3bc8ef-8d50-4883-88ea-c7aaaa1b8d23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3285e13f-f7b0-4b01-82d5-3a01fd7d1487" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_Security12bTitle_3285e13f-f7b0-4b01-82d5-3a01fd7d1487" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ef103f9b-2fc2-4ee2-835e-b6969efe9e60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_TradingSymbol_ef103f9b-2fc2-4ee2-835e-b6969efe9e60" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fabe5551-4149-45f4-bb28-17f25eac318b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_SecurityExchangeName_fabe5551-4149-45f4-bb28-17f25eac318b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2c858847-c497-43fa-9dad-0916212b5dcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityEmergingGrowthCompany_2c858847-c497-43fa-9dad-0916212b5dcc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_28c1a2c3-4c3c-477a-a2da-6899c6c6b2fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityExTransitionPeriod_28c1a2c3-4c3c-477a-a2da-6899c6c6b2fb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ee6efbd6-98fb-4504-9ceb-e2f5dd795724" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityCentralIndexKey_ee6efbd6-98fb-4504-9ceb-e2f5dd795724" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9e576983-05f5-4b1f-b1b5-a96afc0cc2fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_AmendmentFlag_9e576983-05f5-4b1f-b1b5-a96afc0cc2fd" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4ed721a3-1d53-41a3-9ace-f30faede36d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:to="loc_us-gaap_ClassOfStockDomain_4ed721a3-1d53-41a3-9ace-f30faede36d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:to="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d2d62d5-d61d-4ded-acf4-765e107e6652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:to="loc_us-gaap_CommonStockMember_1d2d62d5-d61d-4ded-acf4-765e107e6652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f222b411-eb85-49ea-827f-575faee5ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:to="loc_us-gaap_WarrantMember_f222b411-eb85-49ea-827f-575faee5ea66" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20230512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:20006a8f-5585-4a58-b190-b567a58af272,g:8cba8344-f56d-47b0-9377-d5b25c27f06c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_3e28bfe7-22af-40e7-a7d2-483d2ea66f25_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_874e86b2-c2e3-4c6c-9519-8aec282c8c81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4f155632-a64c-4e0c-a17d-2414062103ee_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_13d0b1e1-8515-40a0-96a9-081b2fbbc7a7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_4fa8629b-323b-438f-ae77-8c7755ef0a2c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_da391ac2-15ab-4b7a-b022-bec9c0e7a22e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_43dae33d-56d2-451c-aa61-ea9d20291e6b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_84f4d1ec-6e13-4953-be54-10df7a8a4eae_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_28a84f1f-61de-4498-a319-2db528e69cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_293d8068-68b7-4b11-82ea-07a71137f5b3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f36053cd-a4a2-4493-aaa7-1d0571f416af_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1cbb5a6e-a270-4efc-b3ac-285fb3a0a8e5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_58ec5a05-f4fa-4aa4-86ed-435cf31f8925_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_3c1f8d7e-96ec-41e8-8b9a-4bd7b68916a6_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_74ba5713-e81c-455b-9d45-e791429870f3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6514aa30-6a07-4e88-944e-d72783ab0f95_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0346aedc-83e3-4e7c-b3e6-69b97e2631ee_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7bd6649f-ca15-4af0-b18d-5befab6865cd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_58b78d10-311f-4619-b8bc-4d6340fb4ecc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3cf773a4-273c-4975-8955-0ac6f53dbbdc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0515aa90-23c8-4e80-a15e-bff069b94027_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c25a6684-da93-4796-a808-f2b717c0f4b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_340e0e98-82f1-4cd2-b196-1c004959ade5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b53bd52f-bd72-496c-ab99-38916ab714b9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b6256d78-a3d9-44cc-9d2d-0e34681959fd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_9b598c7b-f7d9-4075-910e-d6f031535165_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a8b54e02-9c5b-4147-9273-84cb1d24273f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d4e884a5-21da-42bc-a80e-fc5abe414844_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0aa1a5ce-b870-4779-b603-5cf34f55044f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20230512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:20006a8f-5585-4a58-b190-b567a58af272,g:8cba8344-f56d-47b0-9377-d5b25c27f06c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230512.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b5540041-6c2d-42a7-8104-3388079b138c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b5540041-6c2d-42a7-8104-3388079b138c" xlink:to="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4ed721a3-1d53-41a3-9ace-f30faede36d3" xlink:to="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1d2d62d5-d61d-4ded-acf4-765e107e6652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:to="loc_us-gaap_CommonStockMember_1d2d62d5-d61d-4ded-acf4-765e107e6652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f222b411-eb85-49ea-827f-575faee5ea66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_125cd6c0-52eb-4965-84c4-ad9958699f5f" xlink:to="loc_us-gaap_WarrantMember_f222b411-eb85-49ea-827f-575faee5ea66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_4455d30d-e614-4efd-b5b0-1cd93a51db88" xlink:to="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e83fd59-001f-4e29-b0d6-c41948199ce8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_DocumentType_7e83fd59-001f-4e29-b0d6-c41948199ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6d070aed-30a8-4a50-9aba-8116e4867ea2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_DocumentPeriodEndDate_6d070aed-30a8-4a50-9aba-8116e4867ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2a62c530-faf6-4d9b-bd3f-28b1f6986426" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityRegistrantName_2a62c530-faf6-4d9b-bd3f-28b1f6986426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a90fe0a9-f5c8-4bb1-a8ed-bc7cc6c6ecf9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a90fe0a9-f5c8-4bb1-a8ed-bc7cc6c6ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9ee021d9-9d4d-4250-b137-40b06848b2dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityFileNumber_9ee021d9-9d4d-4250-b137-40b06848b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fe0144fe-245e-445c-ac1a-6906b6c2583f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityTaxIdentificationNumber_fe0144fe-245e-445c-ac1a-6906b6c2583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6be245e2-b98e-4246-9dd4-9c96ddff12e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressAddressLine1_6be245e2-b98e-4246-9dd4-9c96ddff12e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2191189e-3711-4725-a4e7-97077288da4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressCityOrTown_2191189e-3711-4725-a4e7-97077288da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_893ba70f-7263-47d5-a573-ca3568d788cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressStateOrProvince_893ba70f-7263-47d5-a573-ca3568d788cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdd8b026-87dc-4587-8775-a0ac2202d47e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityAddressPostalZipCode_fdd8b026-87dc-4587-8775-a0ac2202d47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7ba37b07-97e4-41b2-b4a8-f770f98bef92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_CityAreaCode_7ba37b07-97e4-41b2-b4a8-f770f98bef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4637479e-1fe8-454b-908e-0883d0904ef6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_LocalPhoneNumber_4637479e-1fe8-454b-908e-0883d0904ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_60b71b93-3d0f-44c4-a8ee-f43a69bccbf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_WrittenCommunications_60b71b93-3d0f-44c4-a8ee-f43a69bccbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2aa913de-ae54-423b-a73a-f5a15c7c0ed5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_SolicitingMaterial_2aa913de-ae54-423b-a73a-f5a15c7c0ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a717e342-38f0-435c-a216-65f11e1011a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_PreCommencementTenderOffer_a717e342-38f0-435c-a216-65f11e1011a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2a3bc8ef-8d50-4883-88ea-c7aaaa1b8d23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2a3bc8ef-8d50-4883-88ea-c7aaaa1b8d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3285e13f-f7b0-4b01-82d5-3a01fd7d1487" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_Security12bTitle_3285e13f-f7b0-4b01-82d5-3a01fd7d1487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ef103f9b-2fc2-4ee2-835e-b6969efe9e60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_TradingSymbol_ef103f9b-2fc2-4ee2-835e-b6969efe9e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fabe5551-4149-45f4-bb28-17f25eac318b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_SecurityExchangeName_fabe5551-4149-45f4-bb28-17f25eac318b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2c858847-c497-43fa-9dad-0916212b5dcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityEmergingGrowthCompany_2c858847-c497-43fa-9dad-0916212b5dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_28c1a2c3-4c3c-477a-a2da-6899c6c6b2fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityExTransitionPeriod_28c1a2c3-4c3c-477a-a2da-6899c6c6b2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ee6efbd6-98fb-4504-9ceb-e2f5dd795724" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_EntityCentralIndexKey_ee6efbd6-98fb-4504-9ceb-e2f5dd795724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9e576983-05f5-4b1f-b1b5-a96afc0cc2fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d86d3229-9661-4834-808f-d07e16b32ce4" xlink:to="loc_dei_AmendmentFlag_9e576983-05f5-4b1f-b1b5-a96afc0cc2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MRELR"2*Q9G*LK#!7,QK65WIJ7<UI7E-:O59%!;DFNF)L\ ^ 2BG!/;2D4;C
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MH6G.!3UMTVF.ZG( "B*RO>25^/333\M/T"('J7#050TNO/#"\A-?\4K'[3
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M9&O@_JA1J$[0:UL,3)M <SJCORV$+@\B?%@58B1CE(N7N2K8Q4IOI:""AHG
M_.(2BL8#[F6FQQJ;VK3,G-"2HYEK\"<@$M32BHX@(A5@U&C=EWLL\^V/Z[_R
M28.M4[9)PWIOE 2WBP!SYLS3G_[PYW#$/_D=#P=_?NJIIT(X>BSWJ@'X07B&
M,XB)M'SVV6?+7\\%:# DIG< F(VT $\;!D8B0.CXU6#.,#0P4M#S<Z C(86X
MGBS.P""O,,"<O%V%A$8*PS"\G82=>+AC\KX*^C2W"@)>+AB-H9?TZ02L=,1?
MGP H#YV#E0HZ,HS)*@MAG)D=/%V6JZ EY?-[O[VN'J8J<#]HP>MOE,M5I^H
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MXYJ:7K^6QM2KK0DV:Y]SPS4V _]8N0MFFO0P'2W13F76.<I,NH3S#>4-\H\
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M&=\KGYR.N\7#.7@<1T]O1\#S<_2TD@$W_/U5=^S; YY>2!MZX6;HRW^^/ =
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MZ7Q;8V#:C7+[/ #:LY%#_3'9X(F;K,AL#1*OU=,(4<.5,ZYC',(SX8B#61'
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MR;+'K6 %$#::$%<4(H&>?O G4@))@+7]F%/T[!AS_V6&!E 6^OHDW*?[[!2
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M:&:"5SU$,CH[5^6/6_1;#5:B$?F6^P0LAU\X1(_$"GW&(C(KBTII&,)&SSZ
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M^27,GS\_?'3\P@LO# /1\.'#RP< @#+$A:D+G3CP[&&P5Q4'P8@=0.-E $)
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M60&,YLK^"NF0GO<[GD$T>]J(=L8?'L&$OW$'&7S^YW_^)_ L_,JFK;\ ]?=
M. ?L"!D@8P4IL>'J/A -K A1*0B82 AGQTIARAV-&8)V;=,A0],E#/DM#C>8
MY1L6F:0/>2'%T5#YOGR^,0R=E'4;/K+(13QLP#$:;<FQ9]P0[*9Y8Q9;."Z1
M+LA1:<X&E1B6YB8^DY(;?2J%6]RX>3]<CT>>%,^ SW7/F#M7U]]RJW8U)OQ?
M.O"N?PT-2(>"21@9&2VQQY'1T]%'4Y#1U#>:$* T/@V.ML54>VL:, *8S@%C
MPA!T##1KIM" =S!'(-GNP(D#-MLX ^M,]M___=]AXXGUOV1AZL 2!--K!##E
M@&DYS8%VZ&N&Y.-E1[M":',B "&(0(*)86Z$&VGY]-[+&N^0"%EF&P@$CT?>
M+&>@C3L@@%VC\WHBS%G*(%\Z%!T(@<*Z+\L!<6$?SQ.@W)R39I.*>I(O[45Y
MH8'G0=OXE-[=6)8B7]J;^I(O/(/VQ.!&V@!QD]O,<5NPO>'B0'CRBY>5,CC-
M$"@L):'MTZ[0VX46LP"$&$LY7E\?]'86O#Q>%DP7P&BCO_G-;P)?0D,$\,XN
M0?B:/#STO__[OZ$MJ1>S,P953J:@ #";9.;CR+,CS_0U[!S]8T\FOGFWLU!)
M RZW5'*L !XA-S(693>A\ :,FL$C>2@CKOW%P\:;RT.#\32YP0QY:^T;EC@J
M/")DHXQWV,--_N&*29L6<MXLWU(!"TR(&I8D3C]P%66N"?0M907**<O7EE+#
MDNCSV]Q]&C+AK%HXKV;Q@]J.<ZGFF "^X:8;]6<3O+_Y[?_HOXTI$ "LB[&I
MP_26*2N(MH4)D[H;=D?",G5C)YQ3 ^SNPN@P&0(X60.F<P P.NXP 1HP@M*%
M LL!\6ETO%-CNMV?'2@'4TDVI"@#C+G++KN$HVT(4SJ9@Z<-($QY!9,.20=Q
M 8P&'!? E /T?.D\I,L96)91V'1DPPN:>;DPO?P.:*F\,LI Q: #HDTC"%EK
M=2 > A@D3];;6;^$/G0\R@K-H!\=COLN$.X@@IRT.&DR;MRX8&<MGA<"T)01
MO- :NA,?040<\@0H+WDZG3!95X1'J"OQ?OO;WX:!EF46!K[D*;S'Q\W=>79Z
MN#_H0!LA7!B<*3,T1BC$P\3CN7O\F?3C@I0CDM29,L,3"%\$(%-UWM[T-,@[
MGL[. /&\;OZ, &8/@9,N\"-M1ONA?+ 6NS, K5E#9D"A3K0% MB/7*+ ,!C[
M?@WH^SK^C(( XL8 "YV=;CM;?V"7(&P<0T()Q(XU 5AI(E@.-%$5S! ,SV"Q
M$$&#1(^UJ7Q UVV-D0R-Y!883$0,<>V?J &M00TYKQ@^V!G*9AX)#,=6+"#G
M=PLLKWQ#S'#?:%@^L&F=88$)U?PRT,*87Y[YY1MR-VF!,1VG.0I-RH?SP8GB
M1^4@7W,TX/-#<^:8 +[^1OWICW\.# '6K5<W:#(["ZQQTCE9 T4P@*QO(BP0
M. [>*0 T4C;^$-J4 <$'LEF$,$\>D6$*UPCC0,=A&LPF"NN2,"(# &DAY)CN
M^^86:20S%QT= 8Q0^J__^J\0#Z'"FEC\A1#*3N=V 0)0'@8MIO=L*B(PG($I
M9U6,S,##4H!/Y>E T I!GJP!NT $$.QT.F8,"$_*Z1H[\5G&0 /'GS5]T$\M
M@.Z&YDI\D Y,&5BS1R"0/W5R2*874U]>5V6]&^%+QT>@(931PO&#GLDOTCA-
M0+?'@>4A!@NFP9R9AB= [&QL,G@X+:J*[^!YQ(%I/@(8'D,(,^ A %F:8GW>
M@71!A^KRV!H0AW+&X\+G;(PQ0%,&9@^T/>>V=_84!(,42R>T 3Q+O6A7!G;.
M>2?WD1T!:)!<AQV!7<*.$\BMX['3#Y:B80A3#CPZE@,/M(,+2DO#R!K$;:']
M\ME.;*:6)A#-"N8@K,7Q!$-\1P0MHXMA2(_-P,2&H G4J/$M%TNBV,P@;"V/
M7/L%\PQYYF;^0O,+7\DU(G'TK,2$;OA@:)$QMU63,[]!\"=*561EXFH]@'Q@
MYNNONTY__/T?*@1PW;KA;2\7>! _&9,A[L8:(9?)T&E@")C,A4JR  [E3G0F
MA!>;>FP>($P01@@4! *=G#01;FA?,+(?TD>K0+-!8# UAO$0,@@4XI,. A7!
MRG* :[* E\&!Z3<='0:&%@@5!/!77WU5:=F"^GI<-UU(\LQ @)UPV%VC2@:T
M>Y8@$%SDQ6!%?7TIP,'CDH>_:8@V3QD1F@A7M"K6O*$5RT0L#;$DQ-( ;BS'
M@#SCQ_(2[@Q4;)(BB"@#0@GZL6D:/XD1+S]U!-"8V'QC;=5G#;0=94*3)WW.
M-".,N8."61/+0VA;KGDQ4/G A8 E7Y:QH(/3!#ZBC,G:.73UL@"4L2HZNUM<
M (.4%<&%!AQ7.D@3K"JM'85X&@PN"& $/OE3-Q0#UM1W5@#3WQ#@\#II0BL4
M#S:#&<3@,82TSUBA-1B?O28CIV6(1]H,H$[O'85=(H'H&!/ 020E .OV8H4E
M8=+XI!?/@\+B[N$,$M%H#"X#B80O8CR._,4%G:5B/[Q)8Z$M]6@U.=R$#\(@
M:-&674#+$EX,'Q'%;O&CL!8F9(\]$OQ 26F^9LR<K*NNODR_^_UORIF2Y0($
MF8^<7AYG2F=,=\., XW-D2AVE$F/$1D!F"R 76!Y?-)"N'(@'J& $(2I$."^
MOLD:+IM>:(VL;Z%I(3!YH8%.ZSO[GB]"F,[%9AY363\365W9T=C0DF%@IP=K
MABQ!Q#4YXB4C=7%TMSBMJ@+6Q+G_ H%%9P2I)W5C.<3!XR.P$&9H4&BM=#8&
M+([K43\T:A ZDS;H;MCI6'&DD[&4P7$U!+AK4-0;#9FU;09ISY_ZQ.E&7:$I
M2QW<Y8%P1_ RH##PT6ZT(>W/C(@!@/HBL+WM.&6"H/8C=-# VX\Z4@[:@"4E
MRHQ63K[;@JIHSN#%0.QM2_G(@\&,O0&/$S>K2F=' 'H!I(.R@*8-'WL9H-7?
MLP;,$@0GB* S-(.7J!-*#_E <XZ],1C[@(R9/"CCYF$9H!'@:-:<)6:PW!DH
M?Q'#T<@0PP3$G0+:3PRCOX2780 L)!=HZS[NX,]@'#RMZ*]RN.2PE<&+4PDJ
M1>6'O*WS)\Q@-RW9OW]543[0AHNB0M-PIEKC7V?:S]^LP_PN,#]"# W8IY\P
M#@SOC 3$F3*926$(EB!H?)\6TXG0;.("."ZLW 30JIB"LHQ 9V5#$ T/C0CF
M@FE=LW9A@4E>3.?0Q-@$A)G85$#S\K.P+D#B&"^[+T' O*1/?JP!5[4$D1P_
MG@[@^6'&P\3#(1010FPXTA$9,%@V0$N+"V  NC"EA":^WH?P9;D@KJGN#""8
M$.*<!/!=<_)@">BYYYZKM!$*>MO%@9D% I)SKBP;T8$YTXPV3?UH']H)],&&
M=G2A#Y^P>P__T>8,M!RO@O8L*_G@"233-DY3P/W!.#!38BG,9U<(*LK&AB*:
M*1HU$*];<MK;"\EEX!DZ<@X=98'Z0Q,&)P3=SIZ"\"4(VLW[ %H]"$]13V82
MU-F%,R;NR<CL!],'!@8^VC,^:]P1J/84!,BSNU?8K3'ME[_*^JD)B42XT!SQ
MA*K#&) JZ4:8\$P.7PD]?"+T+_P36 Y> [36"BQ?VC!_S]VAJ+!4LV;.U]UW
MWJ^&]9M8@[$3_]>P<84V0(=W2&9V1W>/ P*8VYF8!J/-H=70$=FIC;^(X<SI
M"-/[U)UGEA?0B-FMYTT?ILRD18=U[2&."$R6/3A#RT804RG2<&'AZ8+)]7!
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I7^%7^#?!KP+X5_@5?H5?X=\"TO\'GVM_Z3P1[XL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140105954146112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20230512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20230512.xsd" xlink:type="simple"/>
    <context id="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <context id="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <context id="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN180L2ZyYWc6YjNjNzRiOTRlZWVhNGNjZWFlMjAyODUzYzU3ZjE1NWYvdGFibGU6ZjRkYTBhZmVjMTk1NGE5NzlkMzgyYmNkOTk1YTY0MTIvdGFibGVyYW5nZTpmNGRhMGFmZWMxOTU0YTk3OWQzODJiY2Q5OTVhNjQxMl8xLTEtMS0xLTgyMDIw_2925a37e-3e65-4fbb-8afd-f1c71a092ca3">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN180L2ZyYWc6YjNjNzRiOTRlZWVhNGNjZWFlMjAyODUzYzU3ZjE1NWYvdGFibGU6ZjRkYTBhZmVjMTk1NGE5NzlkMzgyYmNkOTk1YTY0MTIvdGFibGVyYW5nZTpmNGRhMGFmZWMxOTU0YTk3OWQzODJiY2Q5OTVhNjQxMl8yLTEtMS0xLTgyMDIw_cb0e7331-bef2-404b-bf59-791221480a85">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjI5_f21a16f2-6c84-4e13-8da8-cf64f10a4ea7">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMw_447823fd-a6e9-44b4-bc99-51e757ee7c7b">2023-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMy_afef7265-bf93-4e66-a796-c2b880ae9cf0">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTAtMS0xLTgyMDIw_17b10c9c-de12-43aa-9b59-e62ca6536d07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTEtMS0xLTgyMDIw_12bff9bd-1d9b-4efa-83fb-2262b2444b41">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6OTczZmI3ZTZjZDcxNDVkZThiMGI0MmFhYTA3Y2I2YjUvdGFibGVyYW5nZTo5NzNmYjdlNmNkNzE0NWRlOGIwYjQyYWFhMDdjYjZiNV8wLTItMS0xLTgyMDIw_59c53e02-1d49-46e4-b3a2-88fdd51423f2">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8wLTAtMS0xLTgyMDIw_1987bb04-ac80-4e53-8908-5debe8ee4444">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTAtMS0xLTgyMDIw_4a872a53-a061-4a52-b5d7-b77b29c95dd2">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTEtMS0xLTgyMDIw_7519f0f2-62f6-4d73-b9a1-b1562dc73c5f">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MmJmNDI2ZWM1MTdhNDIxOGE0NTRjNTZlZjRlZjRmZDAvdGFibGVyYW5nZToyYmY0MjZlYzUxN2E0MjE4YTQ1NGM1NmVmNGVmNGZkMF8xLTItMS0xLTgyMDIw_7aa39407-fe0a-4882-ad97-3dbb60c6db38">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8zMjc_326dbb38-8b87-4870-8098-079580976460">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjMz_e155d3d6-0d87-479d-b05d-1f9f71abff39">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18wLTAtMS0xLTgyMDIw_89e26ea0-f87c-4956-9c28-e4874394661a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18xLTAtMS0xLTgyMDIw_a7fde561-86d2-4888-a493-214e9e9155f8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18yLTAtMS0xLTgyMDIw_9f7486ee-8cd4-4e84-a991-9ef405a31e05">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6MjRmM2RkYzM4YjAxNDRkNDk5NzZkMzg4MTU2YWFmZGMvdGFibGVyYW5nZToyNGYzZGRjMzhiMDE0NGQ0OTk3NmQzODgxNTZhYWZkY18zLTAtMS0xLTgyMDIw_9a9607ec-c4b6-437f-ab4a-a61ddcfd1ccb">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTAtMS0xLTgyMDIw_5cab5d14-2a92-4ebe-8894-3d202057521f">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTItMS0xLTgyMDIw_dc4fe450-64cf-4ea7-a421-d69482b31486">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i18f633fedacc45be96dcd2d88bf489c5_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8xLTQtMS0xLTgyMDIw_6eae6334-00b8-4afd-992e-295457881956">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTAtMS0xLTgyMDIw_46614242-5be8-4ddf-b663-8ecddafd098d">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTItMS0xLTgyMDIw_9009b51b-c893-416b-8f7e-fd1ec70eb989">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6c7bdc6cb4c141808ca1e532127a7e6a_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGFibGU6NGNkNDEwYzgwOTAzNDY3MGE4Nzg1ZmVlYjg0YmVkZTYvdGFibGVyYW5nZTo0Y2Q0MTBjODA5MDM0NjcwYTg3ODVmZWViODRiZWRlNl8yLTQtMS0xLTgyMDIw_4a80e7c3-d8ec-4e23-9f79-da9f1ea51f36">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjM0_b7eb74bf-b9bc-4cf6-9b8f-a7edd4d9cdbe">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5MTBlMTdiZTliYzRiYmQ4ZjRkZjE4NzQyZGQwYWQ3L3NlYzo1OTEwZTE3YmU5YmM0YmJkOGY0ZGYxODc0MmRkMGFkN18xL2ZyYWc6MzYxY2RjM2FlMTAyNGExMWE4ZTQwMTE2MjAzMGM3MDEvdGV4dHJlZ2lvbjozNjFjZGMzYWUxMDI0YTExYThlNDAxMTYyMDMwYzcwMV8xMjI4_ced6e777-b225-4a0f-9796-894dc0872d22">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M86#+*^?P(O++[%<RY4$.1:,^(W&E#\;M+7=51RA> 6!AA]9TINMD)FM+2(/
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( *PYK%89117U-P$  "<"   /
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( *PYK%9ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "L.:Q6)!Z;HJT   #X 0
M&@              @ & $@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "L.:Q699!YDAD!  #/ P  $P              @ %E$P
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  "O%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20230512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20230512.htm">huma-20230512.htm</File>
    <File>huma-20230512.xsd</File>
    <File>huma-20230512_def.xml</File>
    <File>huma-20230512_lab.xml</File>
    <File>huma-20230512_pre.xml</File>
    <File>huma-20230512xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20230512.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20230512_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20230512.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20230512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20230512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20230512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20230512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230512.htm",
      "contextRef": "i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230512.htm",
      "contextRef": "i64fbf01e0eb440958c6cb2c50ebe092b_D20230512-20230512",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-23-000028-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-23-000028-xbrl.zip
M4$L#!!0    ( *PYK%:R24T&9A8  )N<   1    :'5M82TR,#(S,#4Q,BYH
M=&WM/6MSXCBVW_=7Z+)[=]-5$5A^F^[.K4P@F<P$TR&D,_"E2[;D8&(P8YL
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MJVMW;6B[WFP$[8OO'?O([K8O#H-:=W]2KYS?M&[.%>B/V!>M:W9TZ#M'Y[J
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MTQG5>YIG12[*BK+6/&]*L^ICL.(^%)BNLCP8BW5>)I;%6<\F_-?[9Z1?(G&
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M   1    :'5M82TR,#(S,#4Q,BYX<V355<ENVS 0O?LK6)U+;;:\"+$#-$&
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MCS[#+V</G)'2TB^O7BQO=W^Z-X=?O?@O4$L#!!0    ( *PYK%8 ^M%,0@T
M %%X   5    :'5M82TR,#(S,#4Q,E]L86(N>&ULU5U=;]LX%GWOK]!FYV$7
M*&.1(B6JF';1S706Q6;:HLV@@RT6!K^4"+6E0%*:Y-\O*=N)/R2;E&R-]J51
M'.KRW&,=WDOR4OWY'P_SF?=#%66:9Z_/X+E_YJE,Y#+-KE^?_7[U*Z!G_WCS
MXL7/?P'@CW]^OO1^R<7=7&65=U$H5BGIW:?5C?=5JO*[EQ3YW/N:%]_3'PR
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M.:\&/[]IQAB%714<M7GSG\=/02$CZDW<MI>]V8)Z<G6C!I8UBEMP+O1\J>P
MLDO'M]2T1@DN#(#5 \JR7DH];\Y82=-LD-W!<(IRPT@8-C$C86(AA[TT5B+O
M"INE /!_5N>&7QH-C>Z6FU)UX]1T-8SG" IPF4)NA-G3OZ9!79/CR";YH>@E
M>D(K]7&O!'D*B$:L?)(J[4YWGHS&[:B%8<.SN\NHG-DZKQ"C A#U521%#YEF
MZ!KY1QP"?%#43P^9EOEZ(&^U$T:K@Y>7QM0>>/.(=B:U86;SZ"+Z(!WV=!T,
M'K?$841 4;)2>MQ0T5#I11,FF6N7*-Q"=J5H:<B^Y".&<A.6TPEH,0R13=$
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MIV[WG4W 05TILG1?6%F6#\;+P\2OAV8,V(F2[EXA18= _==Q"Q;--\'Y\V(
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M(!GZ/_X_4$L! A0#%     @ K#FL5K))309F%@  FYP  !$
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4!08     !@ & (T!  !_60     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
